Spirulina and B Cell Biology: BCR Signalling, Germinal Centres, and Antibody Class Switching

B Cell Receptor Signalling Complex

The B cell receptor (BCR) consists of membrane-bound IgM (or IgD) paired with the signalling heterodimer Igalpha/Igbeta (CD79a/CD79b), each containing a cytoplasmic ITAM (immunoreceptor tyrosine-based activation motif). Antigen crosslinking activates LYN (Src family kinase) to phosphorylate ITAM tyrosines (Tyr183/Tyr194 on Igalpha), recruiting SYK (via tandem SH2 domains), which phosphorylates BLNK (B cell linker protein). BLNK scaffolds BTK (Bruton tyrosine kinase), PLCgamma2, GRB2, and VAV1. BTK (activated by PI3K-PIP3-PDK1/autophosphorylation Tyr551/Tyr223) phosphorylates PLCgamma2, generating DAG (PKCbeta activation) and IP3 (Ca2+ release/NFAT nuclear translocation).

Co-stimulatory Receptors: CD19 and CD21/CD35

CD19 (co-receptor) amplifies BCR signalling: complement-coated antigen engages the CR2/CD21-CD19-CD81 co-receptor complex simultaneously with BCR, reducing the antigen threshold for B cell activation by 1000-fold. CD19 cytoplasmic tail is phosphorylated by LYN and BTK, recruiting PI3K p85/p110delta to generate PIP3, activating Akt and BTK. NF-kB (via PKCbeta/CARMA1/BCL10/MALT1 signalosome) drives B cell survival genes (BCL-2, BCL-XL) and cytokine production (IL-6, TNF-alpha). Spirulina's NF-kB suppression (via PCB) would modestly attenuate B cell survival signalling, potentially relevant in B cell-driven autoimmune contexts.

Germinal Centre Reaction and Affinity Maturation

In secondary lymphoid organs, activated B cells and cognate T follicular helper cells (Tfh, CXCR5+PD-1+BCL-6+ICOS+) form germinal centres (GCs), where: (1) activation- induced cytidine deaminase (AID/AICDA) introduces C-to-U mutations in immunoglobulin V(D)J regions (somatic hypermutation, SHM), creating diversity; (2) positive selection occurs when high-affinity BCR variants capture limiting antigen from follicular dendritic cells and present it to Tfh cells for survival signals (CD40L/IL-21/IL-4); (3) low-affinity B cells undergo apoptosis (BCL-2 low, BIM high). The net result is affinity maturation and memory B cell / plasma cell output.

Antibody Class Switching: AID and Cytokine Control

Class switch recombination (CSR) is also catalysed by AID, which deaminates cytosines in switch regions (S-mu, S-gamma, S-epsilon, S-alpha), creating DSBs resolved by NHEJ. The isotype switched to is determined by cytokine milieu: IL-4+IL-13 (Th2) drives IgE/IgG1; IFN-gamma (Th1) drives IgG2a; TGF-beta drives IgA; IL-10+TGF-beta drives IgA (mucosal). IgE switching requires CD40-CD40L plus IL-4/IL-13 acting on the epsilon switch region. Spirulina's IL-4/IL-13 attenuation (via NF-kB/Th2 reduction from Nrf2-tolerogenic DC effects) directly suppresses IgE class switching, consistent with clinical antiallergy data from randomised trials in allergic rhinitis.

Regulatory B Cells (Bregs) and IL-10

Regulatory B cells (B10 cells, transitional B cells, plasmablast-type Bregs) produce IL-10 and TGF-beta to suppress T cell responses and promote Treg differentiation. Breg induction is promoted by TLR ligands (LPS, CpG), CD40L, and BAFF. IL-10 from Bregs activates STAT3 in macrophages and T cells, suppressing Th1/Th17 and promoting tolerogenic responses. Spirulina polysaccharide TLR4/Dectin-1 stimulation may promote Breg development, contributing to the tolerogenic immune shift observed with spirulina supplementation in autoimmune and allergy models.

Plasma Cell Differentiation and the UPR

Terminal plasma cell differentiation requires massive ER expansion to support antibody secretion (100s of molecules per second). This relies on IRE1alpha-XBP1s (ERSE/UPR element transactivation of EDEM, BiP, PDI, and lipid synthesis for ER expansion) as an essential developmental programme. BLIMP1/PRDM1 drives the GC-to- plasma cell transition (suppressing BCL-6, c-Myc, PAX5). Spirulina's UPR modulation (PCB-NF-kB attenuation of the IRE1alpha-TRAF2 inflammatory arm) would not suppress the XBP1s-ER expansion arm needed for plasma cell function, maintaining antibody secretory capacity while reducing inflammatory UPR.